Mereo BioPharma Group plc Notice of Results (3000J)
03 July 2017 - 4:00PM
UK Regulatory
TIDMMPH
RNS Number : 3000J
Mereo BioPharma Group plc
03 July 2017
Mereo BioPharma Group plc
("Mereo" or the "Company" or the "Group")
Notice of Results
London, 3 July 2017 - Mereo BioPharma Group plc (AIM: MPH), a
clinical stage, UK-based, biopharmaceutical company focused on rare
and specialty diseases, will announce its interim results for the
six months ended 30 June 2017 on Tuesday, 8 August 2017.
For Further Enquiries:
Mereo BioPharma Group
plc +44 (0)333 023 7319
Denise Scots-Knight, Chief
Executive Officer
Richard Jones, Chief Financial
Officer
Nominated Adviser and
Joint Broker
Cantor Fitzgerald Europe +44 (0)20 7894 7000
Phil Davies
Will Goode
Joint Broker
RBC Capital Markets +44 (0)20 7653 4000
Rupert Walford
Laura White
Public Relations Adviser
to Mereo Biopharma
FTI Consulting +44 (0)20 3727 1000
Ben Atwell
Simon Conway
Brett Pollard
About Mereo
Mereo BioPharma is an innovative biopharma company established
to address the R&D and financial challenges faced by an
increasing number of large pharma and biotech companies. Mereo
focuses on developing and optimizing the value of novel medicines
acquired from large pharma and biotech designed to address
significant unmet medical needs in rare and specialty disease
areas.
Mereo is comprised of a strong team with broad operational
capabilities and the financial resources to conduct comprehensive
clinical studies. The Company plans to build a rare and orphan
commercial business combined with plans to partner where
relevant.
Mereo's initial portfolio consists of three mid-late stage
clinical assets that were acquired from Novartis in July 2015 each
with proof of concept data in the indication that Mereo is now
developing. BPS-804 is being developed for the prevention of
fractures resulting from osteogenesis imperfecta (brittle bone
disease); acumapimod (BCT-197), is being developed to treat
inflammation in patients with an AECOPD; and BGS-649 is a
once-weekly oral novel therapy that restores the patient's own
testosterone in men with hypogonadotropic hypogonadism.
In H1 2016 the Company initiated a Phase 2 study with acumapimod
and a Phase 2b study with BGS-649. Mereo recently announced
commencement of the first pivotal trial for BPS-804 and completion
of enrolment of the Acumapimod Phase 2 study. Additional product
opportunities, from a range of large pharmaceutical and
biotechnology companies, are under active evaluation.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORBGGDLLDDBGRR
(END) Dow Jones Newswires
July 03, 2017 02:00 ET (06:00 GMT)
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Apr 2024 to May 2024
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From May 2023 to May 2024